Blood Coagulation: A Potentially Lethal Manifestation in COVID-19 Patients

Varun Tiwari [a*≡] and Abhishek Ingole [a]

[a] *Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (M), Wardha, Maharashtra, India.*

Authors' contributions

This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript.

Review Article

ABSTRACT

Blood clotting is a well-known phenomenon which is intended to provide protection in case of any external cellular/ tissue injury. However, this phenomenon in COVID-19 patients is leading to unusual thrombotic presentations. Since the emergence of novel coronavirus, World has come across various benign as well as lethal manifestations in COVID-19 patients and one such life-threatening manifestation which needs rigorous attention is the genesis of strange blood clots that can travel and get logged into several parts of the COVID-19 patients leading to various clinical presentations. COVID-19 infection is caused due to interaction of spike glycoproteins of coronavirus with ACE 2 receptors on the host cell surface. This interaction in the arteries, veins or capillaries could lead to injury in the vascular wall of blood vessels that can directly/Indirectly lead to coagulation and clotting cascades activation and subsequent formation of internal blood clots. However, it is undesirable to have the presence of these clots as they could lead to certain fatal complications that need emergency medical intervention or else, they may lead to the death of a patient. Due to the severity of this manifestation, early detection of these blood clots in covid-19 patients become very important intervention which could be done by observing certain specific signs and symptoms and/or with the help of various laboratory biomarkers like D-dimer, platelet count, erythrocyte sedimentation rate (ESR), ferritin, fibrinogen, etc. Once the early diagnosis is made, the patient can be treated appropriately with the help of anticoagulant therapy, which includes use of oral and parenteral anticoagulant drugs. This way the complications of blood coagulation like thrombo-embolism, could be prevented.

_____

≡ *MBBS Studen;*
Corresponding author: E-mail: varun.hoshangabad@gmail.com;

1. INTRODUCTION

Severe acute respiratory syndrome (Coronavirus-2), designated as SARS-CoV-2 which was first recognised in Wuhan City, Hubei Province, China, is the causative organism of Coronavirus disease 2019 (COVID-19). On 31th December in2019, it was first conveyed to the World Health Organization (WHO) [1,2]. SARS-CoV-2 is a virus composed of a single strand of Ribonucleic acid (RNA), glycoprotein, spike protein and an envelope. It is a virus of the pulmonary system and so when it enters in the human body, it primarily infects the predominant organ of pulmonary system which is the lung [1]. This access is facilitated by the linking of the receptor-binding domain (RBD) of S1 subunit present on the spike protein of virus with the angiotensin-converting enzyme-2 (ACE-2) receptor of the host which are principally articulated in type II pneumocytes, serving as a pool for the virus [2,3].

The World Health Organisation announced this coronavirus outbreak as a global health crisis on 30th of January 2020 [2.3] Then in the same year on 11th of March, the World Health Organisation declared COVID-19 a global pandemic. Since then, over the course of time with the advent of new mutated coronavirus strains, dynamics of COVID-19 have kept on evolving [3,4].

A major proportion of individuals infected with COVID-19 remain asymptomatic and recover without requiring any medical intervention.

However, common clinical presentations in symptomatic patients include dry cough, sore throat, fever and breathlessness [4]. Although a variety of other symptoms have been seen in patients infected with different mutated strains of coronavirus over the course of the pandemic.

Blood clots have been discovered in the minute blood vessels of various organs like lungs, heart, liver, and kidney, on post-mortem examinations of a significant percentage of COVID-19 patients. These blood clots can cause ischemia of the tissues or organs in which they are logged [5]. Thus, this aspect of covid-19 disease has become an area of research and requires adequate concern. The main objective of this review article is to collect, summarize and present all the important data and information in regard to blood coagulation which has come out to be a most important haematological appearance in patients suffering from covid-19 disease.

The pandemic of Coronavirus disease 2019 (COVID-19) has been producing substantial mortality and morbidity since its outbreak in December 2019. COVID-19 has been linked up with various coagulative disorders and hypercoagulable states in a growing number of studies. Coronavirus infection could trigger numerous systemic coagulative and inflammatory reactions, as per the hypothesized mechanism. Increased production of proinflammatory cytokine is a result of host inflammatory responses, which triggers coagulation cascade activation and consumptive coagulopathy [6]. When compared to historical data, numerous observational studies have found a greater prevalence of venous thrombotic events amid the corona virus infected individuals under intensive care unit (ICU) admission [7]. However, some studies have also testified thrombotic events in arteries of individuals infected with corona virus [8]. Experts urge anticoagulant prophylaxis for all coronavirus infected patients who are seriously unwell.

2. PATHOPHYSIOLOGY

After primary infection, the virus moves into the systemic circulation and attaches itself to the Angiotensin-converting enzyme-2 (ACE-2) expressing endothelial cells that form the lining of the blood vessels. This linkage aids the virus, resulting in injury to endothelial cells and harm to the surface of blood vasculature. The injury to the vasculature can also happen because of inflammation in endothelial cells that can lead to cytokine release and subsequent blood vessel injury. Following injury to endothelial cells in blood vessels, recruitment and aggregation of platelets together with collagen takes place at the place of injury. This aggregation is enhanced by the release and action of the Von Willebrand factor. Coagulation is initiated by activation of the coagulation cascade following the intrinsic pathway. The genesis of clots in blood vasculature can be initiated following sequential activation of all the twelve clotting factors, followed by conversion of prothrombin to form thrombin and then conversion of fibrinogen to form insoluble and elongated fibrins. These fibrins cross-link with platelets by covalent bonds which results in formation of a firm interlocking

network of fibrin clots at the location of injury. This leads to formation of haemostatic plugs. This haemostatic plug can lead to various complications, of which thrombosis is one of the most commonly perceived complications among Covid-19 individuals.

Virchow described three primary events which predispose to thrombus formation and are collectively known as Virchow's triad. It includes:

2.1 Endothelium Injury

It triggers platelet activation and genesis of thrombus by the action of von Willebrand factor (vWF) and tissue factor in the heart and in the arterial circulation, where coagulation is impeded by high rates of blood flow. Activation and adherence of platelets is an important prerequisite for formation of thrombus and therefore clots in arteries and heart are exclusively rich in platelets. Hence, in cases of coronary artery disease and acute myocardial infarction, platelet-inhibitors like aspirin, etc are brought in use. There are several prothrombotic events that can lead to what is called endothelial activation or dysfunction. These events include varied exposures to infectious agents, physical injury, altered blood flow, mediators of inflammation, abnormalities of metabolism such as hypercholesterolemia or homocysteinemia, and toxins assimilated from cigarette smoke.

Following are some important prothrombotic alterations:

- Procoagulant changes - On activation by cytokines, endothelial cells reduce the thrombomodulin expression, which is a main regulator of thrombin activity. This can cause continuous thrombin activation, causing stimulation of platelets and augmentation of inflammation through Protease-activated receptors (PARs) expressed over platelets and other inflammatory cells. Along with this, the inflamed endothelium also reduces the activity of anticoagulants like protein C and tissue factor protein inhibitors.
- Antifibrinolytic effects - Cells of endothelium on activation release plasminogen activator inhibitors (PAIs)that limit lysis of fibrins.

2.2 Altered Blood Flow (Stasis or Turbulent)

Normally, blood flow in vessels is laminar in such a way that the platelets and other cellular elements flow in the centre in the lumen of vessels, around this central flow of cellular elements is the layer of plasma which moves slowly and separates it from the endothelium. Endothelial injury is caused by turbulent flow which leads to formation of counter-currents that contribute to cardiac and arterial thrombosis. Whereas, the major cause behind formation of venous thrombi is stasis.

- Abnormal flow of blood promotes endothelial activation, which enhances procoagulant activity and leukocyte adhesion.
- It disturbs laminar flow and platelets come in contact with endothelium.
- It also safeguards the removal of active clotting factors by and inhibits the inflow of inhibitors of clotting factors.

Altered blood flow aids thrombosis in several clinical syndromes such as aneurysms, acute myocardial infarctions, rheumatic mitral valve stenosis, polycythaemia vera, sickle cell anaemia, etc.

2.3 Hypercoagulability of Blood

Hypercoagulability, also known as thrombophilia, is defined as any haematological disorder predisposing to thrombosis. Hypercoagulability particularly contributes to thrombosis of veins. It can be classified as primary disorders that are genetic and secondary disorders that are acquired. The most common events leading to thrombophilia are point mutations in the prothrombin gene and factor V gene.

One of the mutations leading to hypercoagulability is mutation of a single nucleotide in factor V, called factor V Leiden. This mutation leads to substitution of glutamine by arginine at 506 amino acid residue that results in factor V becoming resistant to splitting and deactivation by protein C, resulting in loss of an antithrombotic counterregulatory pathway.

Another single nucleotide mutation in the prothrombin gene at the 3′- untranslated region can be linked to hypercoagulability. It leads to raised levels of prothrombin and a threefold increase in venous thrombosis.

Apart from above mentioned genetic factors, raised homocysteine levels also aid in thrombosis of arteries and veins. Increased levels of homocysteine could be due to an inherited deficiency of cystathionine β-synthase [9,10].

3. CLINICAL PICTURE

In general, the location of blood clot in the body determines the clinical features a patient suffers:

A blood clot in heart or lung could cause-

- i. Chest pain
- ii. Shortness of breath
- iii. Upper body discomfort in the arms, back, neck, or jaw

A blood clot in the brain could cause-

- i. Headache
- ii. Paralysis
- iii. Dizziness
- iv. Trouble in speaking or understanding speech

A blood clot in deep veins of the leg could cause-

- i. Pain
- ii. Redness
- iii. Warmth
- iv. Swelling

Corona positive individuals can come up with a variety of abnormalities of coagulation as well as complications of thrombosis, some of which are as follows:

- Pulmonary embolism (PE)
- Venous thromboembolism (VTE)
- Sepsis-induced coagulopathy (SIC)
- Disseminated intravascular coagulation (DIC)
- Thrombotic microangiopathy
- Microvascular thrombosis
- Micro-thrombosis

3.1 Laboratory Findings

Following are some of the potentially useful Laboratory findings in COVID-19:

3.1.1 Tests in which levels are likely to increase

- C-reactive protein (CRP)
- D-dimer
- Activated partial thromboplastin (aPTT)

- Aspartate aminotransferase (AST)
- Alanine aminotransferase (ALT)
- Lactate dehydrogenase (LDH)
- Fibrinogen
- Prothrombin time (PT)
- CBC (platelets and lymphocytes)

The levels of above-mentioned markers are usually expected to increase in the acute stage of the disease.

3.1.2 Tests in which levels are likely to decrease

- Albumin
- Activated partial thromboplastin (aPTT)
- CBC (platelets and lymphocytes)
- Fibrinogen
- Prothrombin time (PT)

The levels of above-mentioned markers are usually expected to decrease in the late stage of disease.

There are specific laboratory markers which are helpful for diagnosis, treatment and prognosis of blood coagulation and its related disorders in patients with COVID-19. These include

- **D-dimer**: D-dimer is an outcome of denaturation of fibrin. It is one of the fragments of protein formed on termination of a blood clot in the body . In normal circumstances, it is either undetectable or detectable at a very low level. It is detected only when there is formation and breakdown of blood clots in the body. It's presence in blood indicates fibrinolysis [11]. In patients with COVID-19, raised D-dimer readings are observed to be associated with bad prognosis and increased mortality. In patients with COVID-19, Systemic Inflammatory Response Syndrome (SIRS) leads to coagulation cascade activation which ultimately is responsible for such high D-Dimer levels [12].
- **Platelet count**: Platelets are also designated as thrombocytes. These are colourless bits of blood cells that prevent or stop bleeding by forming clots. Thrombocytopenia is detected in corona-positive patients but the incidence varies as per the severity of disease. Severely diseased patients have a platelet count ranging between 23 ×109/L to 31 ×109/L on average, which

is lower as compared to those with non-severe disease. Platelets are involved in inflammatory signals as well as the immune response. Platelets may assist target haemostasis and immunological responses against possible infectious agents to limit microbial invasion by combining thrombotic and immune recruiting roles.

- **C-reactive protein (CRP)**: It is considered to be an "acute stage protein"that is an early marker of any infectious or inflammatory conditions. Normally, the concentration of CRP in blood is less than 10 mg/L. Although within 6 to 8 hours, it rapidly increases and peaks within 48 hours from the disease onset [13]. Half-life of C-reactive protein is about 19 hours and when the inflammatory stage ends, its concentration decreases.
- **Erythrocyte sedimentation rate (ESR)**: It is a procedure or method to evaluate blood by measuring the speed of sinking of erythrocytes (red blood cells) at the lowermost part of a test tube. Raised ESR can lead to various joint abnormalities like osteoarthritis, it can also be seen as a precursor of renal and hepatic dysfunction; therefore raised ESR in individuals with COVID-19 could be a sign of bad prognosis.
- **Fibrinogen:** Fibrinogen is a complex of glycoprotein that is synthesized in the liver. It is enzymatically converted by thrombin into fibrin as a consequence of any tissue or vascular injury [14]. The fibrin clots so formed primarily act to occlude blood vessels in order to stop bleeding. Several studies have found remarkably higher fibrinogen levels in critically diseased patients.
- **Ferritin:** It is an intracellular iron-storage protein. Various studies have suggested elevated levels of serum ferritin in individuals with severe COVID-19 disease [15]. In autopsies of 12 patients with COVID-19 as a cause of death, raised levels of serum ferritin were found [16].
- **Procalcitonin:** Procalcitonin is the precursor of calcitonin, which regulates calcium homeostasis. preprocalcitonin is cleaved by endopeptidase to form procalcitonin. The level of procalcitonin can reflect the severity of disease in corona positive patients.

4. TREATMENT

The treatment protocols for Covid-19 disease have kept on changing with the course of the pandemic. In general, the treatment for covid-19 is definite and is based on the severity of disease and presence or absence of some risk factors. Currently, a wide range of therapeutic modalities are available for management of COVID-19 under Emergency Use Authorization (EUA) issued by the Food and Drug Administration (FDA). These include: -

- Anti-inflammatory drugs
- Anti-SARS-CoV-2 monoclonal antibodies
- Antiviral drugs
- Immunomodulators agents [17].

Anticoagulant drugs are usually used to treat blood clots. These drugs not only prevent existing clots from getting bigger but they also keep a check on new clot formation [18]. One observational study examined the effects of anticoagulants in people who were hospitalized with COVID-19. It found that people who were treated with anticoagulants in the hospital had a more positive outcome than those who were not [19]. Therefore, WHO recommends the use of low dose anticoagulants in hospitalized patients for preventing the formation of blood clots in blood vessels.

Table 1. Parenteral anticoagulants

Indirect Thrombin Inhibitors	Direct Thrombin Inhibitors
Heparin (unfractionated)	Bivalirudin
Low molecular weight heparins (Enoxaparin, Reviparin, Nadroparin, Ardeparin, Parnaparin)	Argatroban
Fondaparinux	
Danaparoid	

Table 2. Oral anticoagulants

Vit K Antagonists	Direct Factor Xa Inhibitor	Oral Direct Thrombin Inhibitor
Bishydroxycoumarin (Dicumarol)	Rivaroxaban	Dabigatran-etexilate
Warfarin sod.	Apixaban	
Acenocoumarol (Nicoumalone)		
Ethyl-biscoum-acetate		

[20-26]

There are some measures which are certainly helpful in preventing blood coagulation and associated disorders. These are as follows:

- Stay active- A sedentary lifestyle can increase the risk of developing blood clots therefore being fit and active is very important for which regular exercises are very important.
- Lose weight- Shedding excess weight can help lower your risk for developing blood clots.
- Quit smoking- Smoking can harm the blood vessel lining and lead to formation of blood clots.

5. CONCLUSION

Since the time of the emergence of novel coronaviruses, scientists as well as medical professionals around the world have made a lot of progress in unfolding facts related to various aspects of the virus. Based on this study, we can state that blood coagulation is indeed a very lethal manifestation of COVID-19 disease. It occurs as a consequence of endothelium injury which can be due to binding of spike proteins with ACE 2 receptors or due to release of Inflammatory cytokines. This leads to formation of blood coagulants that can ultimately cause various abnormalities of coagulation and complications associated with thrombosis. Although timely diagnosis based on various signs and symptoms, and with the help of various laboratory markers; followed by timely medical intervention using anticoagulant therapy can prevent the patient from entering the state of critical condition or even death.

There is a lot of scope and requirement of research in areas related to COVID-19 as the corona virus is there to stay with us for a long time and we have to find ways to combat its lethal effects on human beings.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Jain A. COVID-19 and lung pathology. Indian J Pathol Microbiol. 2020;63(2):171.
2. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280.e8.
3. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–32.
4. Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic Coronavirus disease 2019 (COVID-19). Cureus [Internet]. 2020; Available from: http://dx.doi.org/10.7759/cureus.7560
5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7.
6. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.
7. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicentre prospective cohort study. Intensive Care Med. 2020;46(6):1089–98.

8. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 10:10.

9. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran pathologic basis of disease, professional edition Ebook . 8th ed. Saunders; 2009.

10. Mohan H. Textbook of pathology. 8th ed. New Delhi, India: Jaypee Brothers Medical; 2018.

11. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, et al. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thromb Res. 2020;192:23–6.

12. Léonard-Lorant I, Delabranche X, Séverac F, Helms J, Pauzet C, Collange O, Schneider F, Labani A, Bilbault P, Molière S, Leyendecker P. Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to D-dimer levels. Radiology. 2020 Sep;296(3): E189-91.

13. Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology. 1991;23(2):118–24.

14. Demelo-Rodríguez P, Cervilla-Muñoz E, Ordieres-Ortega L, Parra-Virto A, Toledano-Macías M, Toledo-Samaniego N, García-García A, García-Fernández-Bravo I, Ji Z, de-Miguel-Diez J, Álvarez-Sala-Walther LA. Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels. Thrombosis research. 2020 Aug 1;192: 23-6.

15. Zhou B, She J, Wang Y, Ma X. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 Novel Coronavirus disease [Internet]. Research Square. 2020.
    Available:http://dx.doi.org/10.21203/rs.3.rs-18079/v1

16. Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Heide RSV. Pulmonary and cardiac pathology in covid-19: The first autopsy series from New Orleans [Internet]. 2020.
    Available:http://dx.doi.org/10.1101/2020.04.06.20050575

17. Coopersmith CM, Antonelli M, Bauer SR, Deutschman CS, Evans LE, Ferrer R, et al. The surviving sepsis campaign: Research priorities for Coronavirus disease 2019 in critical illness: Research priorities for Coronavirus disease 2019 in critical illness. Crit Care Med. 2021;49(4): 598–622.

18. Ouyang X-L, Shu L-Y, Qin X-Y, Yang L. "Evaluations of Hemostatic Activity of Ethanol Extract of Euonymus fortunei Aerial Parts", Journal of Pharmaceutical Research International. 2021;32(46):8-15.
    DOI: 10.9734/jpri/2020/v32i4631097.

19. Bs IP, V F, A L, Md AR, Md Z, Gn N. Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19.

20. Tripathi KD. Essentials of medical pharmacology. 8th ed. New Delhi, India: Jaypee Brothers Medical; 2018.

21. Acharya S, Shukla S, Acharya N. Gospels of a pandemic-A metaphysical commentary on the current COVID-19 crisis.
    Available:https://doi.org/10.7860/JCDR/2020/44627.13774.

22. Arora D, Sharma M, Acharya S, Shukla S, Acharya N. India in "Flattening the Curve" of COVID-19 Pandemic-Triumphs and Challenges Thereof. Journal of Evolution of Medical and Dental Sciences. 2020 Oct 26;9(43): 3252-6.
    https://doi.org/10.14260/jemds/2020/713.

23. Bawiskar N, Andhale A, Hulkoti V, Acharya S, Shukla S. Haematological Manifestations of Covid-19 and Emerging Immunohaematological Therapeutic Strategies. Journal of Evolution of Medical and Dental Sciences. 2020 Nov 16;9(46):3489-95.
    Available:https://doi.org/10.14260/jemds/2020/763.

24. Burhani TS, Naqvi WM. Telehealth--A Boon in the Time of COVID 19 Outbreak. Journal of Evolution of Medical and Dental Sciences. 2020 Jul 20;9(29): 2081-5.
    Available:https://doi.org/10.14260/jemds/2020/454.

25. Butola LK, Ambad R, Kute PK, Jha RK, Shinde AD, DMIMS W. The Pandemic of 21st Century-COVID-19. Journal of Evolution of Medical and Dental Sciences. 2020 Sep 28;9(39): 2913-9.
Available:https://doi.org/10.14260/jemds/2020/637.

26. Dasari V, Dasari K. Nutraceuticals to Support Immunity: COVID-19 Pandemic-A Wake-up Call. Journal of Clinical & Diagnostic Research. 2020 Jul 1;14 (7).
Available:https://doi.org/10.7860/JCDR/2020/44898.13843.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/80463